Tonghua Dongbao soluble sweetener lispro double insulin injection application clinically accepted

On December 27, Tonghua Dongbao issued an announcement stating that the company had recently obtained a notice on clinical trial application acceptance for soluble glorine-lispro insulin injection (THDB0207 injection) issued by CDE

Tonghua Dongbao signed the "Insulin Basic Meal Combination Cooperation and Licensing Agreement" with France SA ADOCIA (hereinafter referred to as "Adocia") on April 26, 2018.

In the third quarter of 2020, Tonghua Dongbao completed the technology transfer, formulation development, and registered batch production, and subsequently carried out preclinical pharmacy and quality research, pharmacology and toxicology research, and formulated a clinical development plan

Soluble insulin glargine and lispro double insulin injection can form a stable double insulin compound preparation at neutral pH by adding new excipients, which can be absorbed during meal time, take effect quickly, and superimpose the transition phase.

Soluble insulin glargine and lispro insulin injection is the only compound preparation that can successfully combine long-acting insulin glargine and fast-acting insulin lispro

At present, the only dual insulin product on the market in my country is Degu aspartd insulin injection.

As of the announcement date, Tonghua Dongbao has invested approximately RMB 26,587,200 in research and development expenses in this project